001024594 001__ 1024594
001024594 005__ 20250804115153.0
001024594 0247_ $$2doi$$a10.1016/S1470-2045(23)00525-9
001024594 0247_ $$2ISSN$$a1470-2045
001024594 0247_ $$2ISSN$$a1474-5488
001024594 0247_ $$2pmid$$a38181810
001024594 0247_ $$2WOS$$aWOS:001157190300001
001024594 037__ $$aFZJ-2024-02268
001024594 082__ $$a610
001024594 1001_ $$00000-0003-0953-7624$$aAlbert, Nathalie L$$b0
001024594 245__ $$aPET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
001024594 260__ $$aLondon$$bThe Lancet Publ. Group$$c2024
001024594 3367_ $$2DRIVER$$aarticle
001024594 3367_ $$2DataCite$$aOutput Types/Journal article
001024594 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738146903_7913
001024594 3367_ $$2BibTeX$$aARTICLE
001024594 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001024594 3367_ $$00$$2EndNote$$aJournal Article
001024594 520__ $$aResponse Assessment in Neuro-Oncology (RANO) response criteria have been established and were updated in 2023 for MRI-based response evaluation of diffuse gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers is increasingly considered for disease monitoring in both clinical practice and clinical trials. So far, a standardised framework defining timepoints for baseline and follow-up investigations and response evaluation criteria for PET imaging of diffuse gliomas has not been established. Therefore, in this Policy Review, we propose a set of criteria for response assessment based on amino acid PET imaging in clinical trials enrolling participants with diffuse gliomas as defined in the 2021 WHO classification of tumours of the central nervous system. These proposed PET RANO criteria provide a conceptual framework that facilitates the structured implementation of PET imaging into clinical research and, ultimately, clinical routine. To this end, the PET RANO 1.0 criteria are intended to encourage specific investigations of amino acid PET imaging of gliomas
001024594 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001024594 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001024594 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b1
001024594 7001_ $$00000-0002-2764-6640$$aEllingson, Benjamin M$$b2
001024594 7001_ $$00000-0001-5710-5127$$avan den Bent, Martin J$$b3
001024594 7001_ $$0P:(DE-HGF)0$$aChang, Susan M$$b4
001024594 7001_ $$00000-0003-4664-1965$$aCicone, Francesco$$b5
001024594 7001_ $$0P:(DE-HGF)0$$ade Groot, John$$b6
001024594 7001_ $$00000-0002-1664-2513$$aKoh, Eng-Siew$$b7
001024594 7001_ $$00000-0001-9644-7496$$aLaw, Ian$$b8
001024594 7001_ $$00000-0002-9408-3278$$aLe Rhun, Emilie$$b9
001024594 7001_ $$00000-0002-6537-3874$$aMair, Maximilian J$$b10
001024594 7001_ $$0P:(DE-HGF)0$$aMinniti, Giuseppe$$b11
001024594 7001_ $$00000-0001-9134-1537$$aRudà, Roberta$$b12
001024594 7001_ $$00000-0002-6656-295X$$aScott, Andrew M$$b13
001024594 7001_ $$00000-0003-4423-7256$$aShort, Susan C$$b14
001024594 7001_ $$00000-0001-5563-2871$$aSmits, Marion$$b15
001024594 7001_ $$00000-0002-1083-8232$$aSuchorska, Bogdana$$b16
001024594 7001_ $$00000-0002-8005-2833$$aTolboom, Nelleke$$b17
001024594 7001_ $$00000-0003-1118-926X$$aTraub-Weidinger, Tatjana$$b18
001024594 7001_ $$00009-0004-1756-423X$$aTonn, Joerg-Christian$$b19
001024594 7001_ $$0P:(DE-Juel1)171957$$aVerger, Antoine$$b20
001024594 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b21
001024594 7001_ $$00000-0002-0774-7700$$aWen, Patrick Y$$b22
001024594 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b23
001024594 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(23)00525-9$$gVol. 25, no. 1, p. e29 - e41$$n1$$pe29 - e41$$tThe lancet / Oncology$$v25$$x1470-2045$$y2024
001024594 8564_ $$uhttps://juser.fz-juelich.de/record/1024594/files/post-print.pdf$$yRestricted
001024594 909CO $$ooai:juser.fz-juelich.de:1024594$$pVDB
001024594 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b1$$kFZJ
001024594 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001024594 9141_ $$y2024
001024594 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
001024594 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
001024594 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
001024594 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
001024594 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
001024594 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-17
001024594 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
001024594 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2022$$d2024-12-17
001024594 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-17
001024594 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-17
001024594 915__ $$0StatID:(DE-HGF)9950$$2StatID$$aIF >= 50$$bLANCET ONCOL : 2022$$d2024-12-17
001024594 920__ $$lyes
001024594 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001024594 980__ $$ajournal
001024594 980__ $$aVDB
001024594 980__ $$aI:(DE-Juel1)INM-3-20090406
001024594 980__ $$aUNRESTRICTED